AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Alnylam launched 'Play by Play,' a U.S. educational initiative for AMVUTTRA (vutrisiran) timed to World Heart Day, featuring former athletes living with ATTR-CM. The campaign centers on former pro football player Pete Shaw, whose ATTR-CM symptoms were initially attributed to football and aging, delaying diagnosis until treatment with the quarterly TTR-silencer.
Key figures
- Dosing frequency
- once quarterly (four times per year) via subcutaneous injection
- Attr patients worldwide
- more than 500,000, ~80% undiagnosed
- Helios b mortality reduction
- 28.2% all-cause mortality and recurrent CV events, 32.8% monotherapy, through 36 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.